"With our robotic platform, we now have a unique tool to explore the potential of many rare microorganisms, both from our proprietary library, our targeted collection activities, and samples provided by our research partners . First bacterial extracts of interest have been identified and are currently being dereplicated , in order to identify the molecule that is causing the antibiotic activity and verify its innovative character. We want to move fast because antibiotic resistance is progressing rapidly throughout the world and represents a major danger to mankind with projections on deaths amounting to 10 million from 2050 onwards  ," says Georges GAUDRIAULT, Scientific Director of DEINOVE.
The division Next-generation anti-infectives which is one of DEINOVE's strategic pillars was initially developed by DEINOBIOTICS, a subsidiary wholly-owned by DEINOVE. A decision was taken to merger DEINOBIOTICS into DEINOVE through a total asset transfer on November 1, 2018, after whichDEINOBIOTICS was removed from the Trade and Companies Register.
 DEINOVE has initiated research collaborations with the Italian biotech company Naicons and the diagnostic specialist bioMérieux, which provide the Company with a range of diverse strains. Other partnerships of this nature are under discussion.